What does pseudoallergy mean in chronic spontaneous urticaria (CSU) and what are the latest updates?

Pseudoallergy in Chronic Spontaneous Urticaria: Current Understanding

Pseudoallergy in CSU refers to non-IgE-mediated reactions to naturally occurring food compounds (pseudoallergens) and histamine-rich foods that can trigger or exacerbate urticaria symptoms through direct mast cell activation, rather than through true allergic mechanisms.

What Pseudoallergy Means

Pseudoallergic reactions differ fundamentally from true type I allergic reactions:

• Mechanism: These reactions bypass IgE-mediated pathways and directly activate mast cells to release histamine and inflammatory mediators 1
• Triggers: Include naturally occurring compounds in foods (not just artificial additives as previously thought), histamine-rich foods, and certain medications like NSAIDs 1
• Prevalence: In acute urticaria, pseudoallergic reactions to NSAIDs account for approximately 9% of cases 1

Clinical Relevance in CSU

The role of pseudoallergens in CSU is more nuanced than initially believed:

Patient Reporting vs. Objective Evidence

• Approximately one-third (34%) of CSU patients report symptom exacerbation with histamine-rich foods 2
• However, this history alone is unreliable for diagnosis - there is little correlation between patient-reported food triggers and objective testing 2

Dietary Intervention Outcomes

A low-pseudoallergen and histamine-restricted diet can benefit a subset of CSU patients, with response rates exceeding 55% in some studies 1. More recent data shows:

• 46% of patients respond to a histamine-free, pseudoallergen-low diet with clinically meaningful UAS7 reduction (≥7 points) 2
• Benefits appear within 3-4 weeks of dietary restriction 3
• Up to one-third of antihistamine-refractory patients may benefit from this approach 3

Important Caveats

A critical 2016 study revealed key limitations 2:

• Only 17% of patients showed positive responses to double-blind, placebo-controlled oral histamine provocation (75 mg)
• Only 2 of 157 patients were positive across all three domains (history, diet response, and provocation testing)
• The benefit from low-pseudoallergen diets is likely not primarily due to histamine avoidance but rather to reduction of other naturally occurring pseudoallergens

Latest Updates (2022-2026)

Mechanistic Understanding

Recent guidelines and research have refined our understanding 4:

• CSU is now recognized as having distinct endotypes: autoallergic (type I) with IgE autoantibodies to self-antigens, and autoimmune (type IIb) with IgG autoantibodies targeting IgE or FcεRI 5
• Pseudoallergic mechanisms represent non-IgE-dependent pathways that may contribute to mast cell activation 5
• These include MRGPRX2-mediated activation, neuroimmune interactions, and gut microbiome alterations 5

Diagnostic Approach

The 2022 international guidelines do not emphasize pseudoallergen testing in routine workup 4. Instead, focus on:

• Basic tests: differential blood count, CRP/ESR, total IgE, and IgG-anti-TPO levels
• High IgG-anti-TPO to total IgE ratio suggests autoimmune (type IIb) CSU 4
• Autologous serum testing has limited clinical relevance since omalizumab works independently of results 4

Treatment Positioning

Dietary manipulation is not part of the standard treatment algorithm 4. The streamlined 3-step approach is:

1. First-line: Second-generation H1-antihistamines (up to 4-fold standard dose)
2. Second-line: Omalizumab 300 mg every 4 weeks (updosing to 600 mg every 2 weeks if needed)
3. Third-line: Cyclosporine (up to 5 mg/kg body weight)

Newly approved options include remibrutinib and dupilumab for refractory cases 6, 7.

Practical Clinical Approach

For patients inadequately controlled on antihistamines, prioritize omalizumab over dietary trials 4. However, consider a 3-4 week trial of low-pseudoallergen diet in:

• Patients reporting clear food-related symptom patterns
• Those awaiting or unable to access omalizumab
• Antihistamine-refractory patients seeking additional interventions

Do not rely on patient history alone to diagnose pseudoallergy - the correlation is poor 2. If dietary intervention is attempted, use objective measures (UAS7 scores) to assess response rather than subjective reporting.

The evidence suggests pseudoallergy plays a limited but real role in a subset of CSU patients, but mechanism-based therapies targeting mast cell activation (omalizumab, dupilumab, BTK inhibitors) have superseded dietary approaches as the primary management strategy for antihistamine-refractory disease 8, 6.